John Koconis Biography and Net Worth

John has had a highly accomplished career as both a strategic and operational leader in the pharmaceutical sector with over 25 years of experience leading successful teams in global markets and launching multiple market-leading products. John brings a unique perspective through his experience in broad, specialty and rare/orphan dermatology development and commercialization.

As President & CEO of LEO Pharma (US), he opened a successful U.S. affiliate for the European based LEO A/S, establishing a market-leading dermatology company with a primary focus on psoriasis and AK. After 15 years with LEO, John moved to Sanofi/Genzyme where, as the Global Lead for Dermatology and Respiratory Disease, he led the Global launch of dupilumab, the first biologic for moderate to severe atopic dermatitis. After Sanofi Genzyme, John joined Castle Creek Pharmaceuticals as the EVP and Chief Commercial Officer to prepare for the commercialization of the company’s epidermolysis bullosa asset and transition the company towards a commercial stage. This experience across the different areas of dermatology has allowed John to build a broad and diverse network within global dermatology and with KOLs in multiple indications. John holds an MBA from Loyola University Graduate School of Business and a BS in Biology from Loyola University-Chicago.

How old is John Koconis?: Mr. Koconis is currently 53 years old. There are 2 older executives and no younger executives at Timber Pharmaceuticals. The oldest executive at Timber Pharmaceuticals is Dr. Alan Mendelsohn M.D., Executive VP & Chief Medical Officer, who is 60 years old. Learn More on John Koconis' age.
How do I contact John Koconis?: The corporate mailing address for Mr. Koconis and other Timber Pharmaceuticals executives is 50 TICE BLVD SUITE A26, WOODCLIFF LAKE NJ, 07677. Timber Pharmaceuticals can also be reached via phone at (973) 314-9577 and via email at [email protected]. Learn More on John Koconis' contact information.
Has John Koconis been buying or selling shares of Timber Pharmaceuticals?: John Koconis has not been actively trading shares of Timber Pharmaceuticals during the last quarter. Most recently, on Wednesday, December 15th, John Koconis bought 20,000 shares of Timber Pharmaceuticals stock. The stock was acquired at an average cost of $0.38 per share, with a total value of $7,600.00. Learn More on John Koconis' trading history.
Who are Timber Pharmaceuticals' active insiders?: Timber Pharmaceuticals' insider roster includes John Koconis (CEO), Alan Mendelsohn (Insider), and Edward Sitar (Director). Learn More on Timber Pharmaceuticals' active insiders.

John Koconis Insider Trading History at Timber Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/15/2021	Buy	20,000	$0.38	$7,600.00

John Koconis Buying and Selling Activity at Timber Pharmaceuticals

Timber Pharmaceuticals Company Overview

Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.

Today's Range

Now: N/A

50 Day Range

MA: $1.87

$0.34

$2.94

2 Week Range

Now: N/A

Volume

26,307 shs

Average Volume

511,937 shs

Market Capitalization

$1.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.03

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>